Free Trial
Matt Larew

Matt Larew Analyst Performance

Partner at William Blair

Matt Larew is a stock analyst at William Blair focused in the healthcare sector, covering 27 publicly traded companies. Over the past year, Matt Larew has issued 6 stock ratings, including buy and hold recommendations. While full access to Matt Larew's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Matt Larew's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
42 Last 8 Years
Buy Recommendations
59.52% 25 Buy Ratings
Companies Covered
27 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy59.5%25 ratings
Hold38.1%16 ratings
Sell2.4%1 ratings

Out of 42 total stock ratings issued by Matt Larew at William Blair, the majority (59.5%) have been Buy recommendations, followed by 38.1% Hold and 2.4% Sell.

Exchange Coverage

ExchangePercentageCount
NYSE
59.3% of companies on NYSE
16 companies
NASDAQ
40.7% of companies on NASDAQ
11 companies

Matt Larew, an analyst at William Blair, currently covers 27 companies listed on NYSE and NASDAQ, with the majority traded on NYSE.

Coverage Focus

Sector IconSectorPercentage
Healthcare
26 companies
96.3%
Materials
1 company
3.7%

Matt Larew of William Blair specializes in stock coverage within the Healthcare sector, with additional focus on Materials companies.

Coverage Industries

IndustryPercentage
LIFE SCIENCES TOOLS & SERVICES
15 companies
55.6%
HEALTHCARE PROVIDERS & SERVICES
10 companies
37.0%
CONTAINERS & PACKAGING
1 company
3.7%
BIOTECHNOLOGY
1 company
3.7%

Matt Larew's Ratings History at William Blair

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
0 Results
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
11/4/2026Downgrade$13.56Market Perform
Option Care Health, Inc. stock logo
OPCH
Option Care Health
10/6/2026Downgrade$31.00Market Perform
Revvity Inc. stock logo
RVTY
Revvity
10/5/2026Initiated Coverage$157.14Outperform
Bio-Techne Corp stock logo
TECH
Bio-Techne
6/25/2026Downgrade$70.70Market Perform
10x Genomics stock logo
TXG
10x Genomics
3/31/2026Upgrade$19.81Outperform
Waters Corporation stock logo
WAT
Waters
1/5/2026Initiated Coverage$381.97Outperform
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
10/6/2025Upgrade$177.56Outperform
Thermo Fisher Scientific Inc. stock logo
TMO
Thermo Fisher Scientific
8/18/2025Initiated Coverage$488.15Outperform
MaxCyte, Inc. stock logo
MXCT
MaxCyte
8/7/2025Downgrade$2.04Market Perform